TOPLINE: Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. METHODOLOGY: Researchers conducted a multicentre retrospective cohort study involving 73 adult patients (median age at IO initiation...
The Center For Mind & Esteem Development, Inc.
A Course In Personal & Professional Development
LoveNow360 for Self, Community & World
Engagement & Empowerment
Marvin Mack, Founder & Creative Direcotr
The Center For Mind & Esteem Development, Inc. A Course In Personal & Professional LoveNow360 for Self, Community & World Engagement & Empowerment Marvin Mack, Founder & Creative Director lovenow360.net
4109716235
personaldevelopment@me.com
Copyright © 2023 lovenow360worldnews. All Rights Reserved
